The nuclear factor kappa B (NF-kB) signaling system, a key regulator of immunologic processes, also affects a plethora of metabolic changes associated with inflammation and the immune response. NF-kB-regulating signaling cascades, in concert with NF-kB-mediated transcriptional events, control the metabolism at several levels. NF-kB modulates apical components of metabolic processes including metabolic hormones such as insulin and glucagon, the cellular master switches 5' AMP-activated protein kinase and mTOR, and also numerous metabolic enzymes and their respective regulators. Vice versa, metabolic enzymes and their products also exert multilevel control of NF-kB activity, thereby creating a highly connected regulatory network. These insights have resulted in the identification of the noncanonical IkB kinase kinases IkB kinase 3 and TBK1, which are upregulated by overnutrition, and may therefore be suitable potential therapeutic targets for metabolic syndromes. An inhibitor interfering with the activity of both kinases reduces obesity-related metabolic dysfunctions in mouse models and the encouraging results from a recent clinical trial indicate that targeting these NF-kB pathway components improves glucose homeostasis in a subset of patients with type 2 diabetes.